Effects of growth hormone plus gonadotropins on controlled ovarian stimulation in infertile women of advanced age, poor responders, and previous in vitro fertilization failure patients.

Plain-language guide to PMID 29241924 (2017): observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 436 patients.

Key Facts

PMID: 29241924
Journal: Taiwanese journal of obstetrics & gynecology
Year: 2017
Study type: Observational Study
Authors: Ho YK et al. (7 authors)
DOI: 10.1016/j.tjog.2017.10.018

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.

To investigate the effects of growth hormone (GH) cotreatment in ovarian stimulation in infertile women of advanced age, poor responders, and patients with one or more previous IVF treatment failures.

Who Took Part

The study group was 436 patients.

By PubMed's age tags, the people studied were adults, women only.

The researchers conducted a retrospective observational study of 436 patients undergoing GH cotreatment in ovarian stimulation.

The first arm included 134 infertile women of advanced age.

How the Study Was Run

The second arm included 236 patients with one or more IVF previous treatment failures, and the third arm included 66 younger poor responders.

Main outcome measures were the number of oocytes and embryos, quality of embryos, and implantation and pregnancy rates.

What Was Measured

PubMed files the paper under topics including Age Factors, Embryo Implantation, Fertilization in Vitro, Gonadotropins, Growth Hormone, Infertility, Female and Oocytes.

The authors tagged it with the keywords Infertile women of advanced age, In vitro fertilization failure and Poor ovarian response.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 436 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Taiwanese journal of obstetrics & gynecology), a journal based in China (Republic : 1949- ).

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.